What does Pharmaphie SDW do?

Pharmaphie SDW is a pharmacy in Gent. Private Limited, started on 7 September 2012, 1 establishment.

What is the address of Pharmaphie SDW?

The registered office of Pharmaphie SDW is located at Hogeheerweg 63, 9051 Gent.

Is Pharmaphie SDW still active?

Yes. According to the CBE (30 October 2026) Pharmaphie SDW is active, legal situation “Normale toestand”, started on 7 September 2012.

Is Pharmaphie SDW registered on Peppol?

Yes, Pharmaphie SDW is registered on the Peppol network with ID 0208:0848603510.

What is the enterprise number of Pharmaphie SDW?

The enterprise number of Pharmaphie SDW is BE0848603510.

When was Pharmaphie SDW founded?

Pharmaphie SDW was founded on 7 September 2012.

Who are the directors of Pharmaphie SDW?

According to the 2025 annual accounts, the directors of Pharmaphie SDW are: Alexandre Flamant, Pharmaphie Holding BV.

Is Pharmaphie SDW a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 7 September 2012; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did Pharmaphie SDW make in 2025?

Pharmaphie SDW recorded a loss after taxes of € 3,946 in financial year 2025.

What is the revenue of Pharmaphie SDW?

As a small company, Pharmaphie SDW is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 193,543.

How much does an employee at Pharmaphie SDW earn?

The average wage cost per full-time employee at Pharmaphie SDW was € 82,700 in 2025: staff costs of € 107,524 for 1.3 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does Pharmaphie SDW have?

According to the 2025 annual accounts, Pharmaphie SDW has 1.3 full-time equivalents (FTE).

Pharmaphie SDW (Private Limited) - Gent - BE0848603510

Dossier Pharmaphie SDW, printed on 30 October 2026 from databakkes.be/en/0848603510/pharmaphie-sdw. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Pharmaphie SDW from Gent, company number BE0848603510, closed financial year 2025 with a result of € -3,946 after tax. For that financial year Pharmaphie SDW recorded a gross margin of € 193,543 and equity of € 421,867. Compared with financial year 2024, the result moved from € 53,031 to € -3,946. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 22, 2026.

What it is worth Healthy

€ 421,867

▼ 1% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -3,946

▼ still € 53,031 profit in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 18,889

▼ 64% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 362,197.

People and assets in 2025

Full-time equivalents

1.3

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 107,524

▲ 2% vs 2024

€ 82,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Debts at end 2025

Bank debt ≈ 10 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 622,009

▲ 39% vs 2024

€ 65,333 is repaid this year. At this pace the long-term loan is gone in ≈ 10 years.

Owed to suppliers

€ 91,651

▼ 40% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 28,941

▲ 23% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 328,199 Gross margin 2022: € 328,199 First fiscal year in the series	€ 231,780 Gross margin 2023: € 231,780 ▼ 29% vs 2022 (€ 328,199) Unfavourable step	€ 241,399 Gross margin 2024: € 241,399 ▲ 4% vs 2023 (€ 231,780) Favourable step	€ 193,543 Gross margin 2025: € 193,543 ▼ 20% vs 2024 (€ 241,399) Unfavourable step	▼ 20%
Profit after taxes	€ 132,641 Profit after taxes 2022: € 132,641 First fiscal year in the series	€ 48,339 Profit after taxes 2023: € 48,339 ▼ 64% vs 2022 (€ 132,641) Unfavourable step	€ 53,031 Profit after taxes 2024: € 53,031 ▲ 10% vs 2023 (€ 48,339) Favourable step	€ -3,946 Profit after taxes 2025: € -3,946 ▼ € 56,978 vs 2024 (€ 53,031) Unfavourable step	▼ € 56,978
Equity	€ 324,443 Equity 2022: € 324,443 First fiscal year in the series	€ 372,782 Equity 2023: € 372,782 ▲ 15% vs 2022 (€ 324,443) Favourable step	€ 425,814 Equity 2024: € 425,814 ▲ 14% vs 2023 (€ 372,782) Favourable step	€ 421,867 Equity 2025: € 421,867 ▼ 1% vs 2024 (€ 425,814) Unfavourable step	▼ 1%
Total debts	€ 782,005 Total debts 2022: € 782,005 First fiscal year in the series	€ 706,528 Total debts 2023: € 706,528 ▼ 10% vs 2022 (€ 782,005) Favourable step	€ 650,105 Total debts 2024: € 650,105 ▼ 8% vs 2023 (€ 706,528) Favourable step	€ 766,309 Total debts 2025: € 766,309 ▲ 18% vs 2024 (€ 650,105) Unfavourable step	▲ 18%
Cash	€ 144,998 Cash 2022: € 144,998 First fiscal year in the series	€ 54,797 Cash 2023: € 54,797 ▼ 62% vs 2022 (€ 144,998) Unfavourable step	€ 52,414 Cash 2024: € 52,414 ▼ 4% vs 2023 (€ 54,797) Unfavourable step	€ 18,889 Cash 2025: € 18,889 ▼ 64% vs 2024 (€ 52,414) Unfavourable step	▼ 64%
Land & buildings	€ 717,821 Land & buildings 2022: € 717,821 First fiscal year in the series	€ 689,967 Land & buildings 2023: € 689,967 ▼ 4% vs 2022 (€ 717,821) Unchanged	€ 663,227 Land & buildings 2024: € 663,227 ▼ 4% vs 2023 (€ 689,967) Unchanged	€ 636,487 Land & buildings 2025: € 636,487 ▼ 4% vs 2024 (€ 663,227) Unchanged	▼ 4%
Retained profit	€ 264,774 Retained profit 2022: € 264,774 First fiscal year in the series	€ 313,112 Retained profit 2023: € 313,112 ▲ 18% vs 2022 (€ 264,774) Favourable step	€ 366,144 Retained profit 2024: € 366,144 ▲ 17% vs 2023 (€ 313,112) Favourable step	€ 362,197 Retained profit 2025: € 362,197 ▼ 1% vs 2024 (€ 366,144) Unfavourable step	▼ 1%
Dividend	€ 55,000 Dividend 2022: € 55,000 First fiscal year in the series	€ 0 Dividend 2023: € 0 ▼ 100% vs 2022 (€ 55,000) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged	€ 0 Dividend 2025: € 0 Unchanged (€ 0) Unchanged
Bank debt	€ 539,444 Bank debt 2022: € 539,444 First fiscal year in the series	€ 511,111 Bank debt 2023: € 511,111 ▼ 5% vs 2022 (€ 539,444) Favourable step	€ 447,778 Bank debt 2024: € 447,778 ▼ 12% vs 2023 (€ 511,111) Favourable step	€ 622,009 Bank debt 2025: € 622,009 ▲ 39% vs 2024 (€ 447,778) Unfavourable step	▲ 39%
Balance sheet total	€ 1,106,448 Balance sheet total 2022: € 1,106,448 First fiscal year in the series	€ 1,079,310 Balance sheet total 2023: € 1,079,310 ▼ 2% vs 2022 (€ 1,106,448) Unchanged	€ 1,075,919 Balance sheet total 2024: € 1,075,919 Unchanged (€ 1,079,310) Unchanged	€ 1,188,176 Balance sheet total 2025: € 1,188,176 ▲ 10% vs 2024 (€ 1,075,919) Unchanged	▲ 10%
Employees (FTE)	1.4 Employees (FTE) 2022: 1.4 First fiscal year in the series	1.3 Employees (FTE) 2023: 1.3 ▼ 0.1 vs 2022 (1.4) Unchanged	1.3 Employees (FTE) 2024: 1.3 Unchanged (1.3) Unchanged	1.3 Employees (FTE) 2025: 1.3 Unchanged (1.3) Unchanged

Key figures of Pharmaphie SDW, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Pharmaphie SDW?

What happened at Pharmaphie SDW in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 22, 2026 New annual accounts for financial year 2025: loss of € 3,946 (▼ € 56,978 vs 2024). Source: NBB ↗
Nov 1, 2012 New establishment in Gent. KBO
Sep 7, 2012 Start of the company according to the CBE. KBO

In short

From € 132,641 profit in 2022 to € 3,946 loss in 2025.

Paid € 61,019 in corporate taxes since 2022.

Best year ever: 2022, with € 132,641 profit.

On average € 148,900 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

PHARMAPHIE HOLDING 99.8%

The stake of PHARMAPHIE HOLDING comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

Pharmaphie SDW

Behind Pharmaphie SDW are Alexandre Flamant and Pharmaphie Holding BV. The shares are held by PHARMAPHIE HOLDING (99.8%).

Directors

According to the 2025 annual accounts

Alexandre Flamant

Director

Also active at: NMB Projects

Pharmaphie Holding BV

Director · represented by Sophie De Brabandere

Also active at: Pharmaphie EVG, PharmaSpace

Shareholders

PHARMAPHIE HOLDING

99.8%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Hogeheerweg 63

9051 Gent

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.

All companies at this address →

NMB Projects same network

€ 39,867 gross margin · 2025

PharmaSpace same network

€ 321,507 gross margin · 2026

PHARMAPHIE HOLDING same network

€ 33,848 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0848.603.510
VAT number: BE 0848.603.510
Registered office: Hogeheerweg 63, 9051 Gent
Names & denominations: Pharmaphie SDW
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 7 September 2012
Peppol: Active · Active since 21 Oct 2026
Activities · NACE: Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗